Volume 6 Supplement 2

Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2010

Open Access

Non-inferiority efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma

Contributed equally
Allergy, Asthma & Clinical Immunology20106(Suppl 2):P33

DOI: 10.1186/1710-1492-6-S2-P33

Published: 22 December 2010

Background

Mometasone furoate/formoterol (MF/F) combination therapy is a new treatment for persistent asthma. We report findings from a non-inferiority study that compared effects of MF/F and fluticasone propionate/salmeterol (FP/S) combination therapies on pulmonary function and onset of action in subjects with persistent asthma.

Materials and methods

This randomized, active-controlled, multicenter, non-inferiority trial enrolled subjects (≥12 yrs) previously treated with medium-dose inhaled corticosteroid alone or combined with a long-acting β2-agonist. Following a 2-4 wk run-in treatment period with MF administered via metered-dose inhaler (MDI) 200 μg twice daily (BID), eligible subjects were randomized to MF/F-MDI 200/10 μg BID or FP/S administered via dry-powder inhaler (DPI) 250/50 μg BID for 12 wks. The primary endpoint was change from baseline in area under the curve in forced expiratory volume in 1 s 0-12 h postdose (FEV1AUC0-12 h). Key secondary endpoints included onset of action, defined as change from baseline in FEV1 at 5 min postdose on Day 1.

Results

722 subjects were randomized to MF/F-MDI (n = 371) or FP/S-DPI (n = 351). MF/F-MDI was found to be non-inferior to FP/S-DPI for mean FEV1AUC0-12 h at endpoint (3.43 vs 3.24 Lxh, respectively; 95% CI, -0.40, 0.76). MF/F-MDI's onset of action was rapid and significantly faster than observed for FP/S-DPI (Figure 1), with a 200 mL mean increase from baseline in FEV1 at 5 min postdose (first scheduled measurement) on Day 1 for MF/F-MDI vs 90 mL for FP/S-DPI (P < 0.001).
Figure 1

Onset of action for MF/F-MDI vs FP/S-DPI combination therapies.

Conclusions

This non-inferiority trial demonstrated that MDI-administered MF/F 200/10 μg BID was non-inferior to DPI-administered FP/S 250/50 μg BID in FEV1AUC0-12 h. MF/F-MDI was superior to FP/S-DPI in onset of action.

Notes

Authors’ Affiliations

(1)
University of Cincinnati College of Medicine
(2)
Boys Town National Research Hospital
(3)
Merck Research Laboratories

Copyright

© Bernstein et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement